Dementia with Lewy Bodies (DLB), Parkinson's Disease (PD), and Multiple System Atrophy (MSA) Are Synucleopathies Characterized by Increased Serum Levels of Plasminogen Activator Inhibitor-1 (PAI-1)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F25%3A00082461" target="_blank" >RIV/00159816:_____/25:00082461 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/25:10498786 RIV/00064203:_____/25:10498786

Výsledek na webu

<a href="https://pubs.acs.org/doi/10.1021/acsomega.4c10959" target="_blank" >https://pubs.acs.org/doi/10.1021/acsomega.4c10959</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1021/acsomega.4c10959" target="_blank" >10.1021/acsomega.4c10959</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Dementia with Lewy Bodies (DLB), Parkinson's Disease (PD), and Multiple System Atrophy (MSA) Are Synucleopathies Characterized by Increased Serum Levels of Plasminogen Activator Inhibitor-1 (PAI-1)

Popis výsledku v původním jazyce

Dementia with Lewy bodies (DLB), Parkinson&apos;s disease (PD), and multiple system atrophy (MSA) are neurodegenerative disorders characterized by abnormal accumulation of alpha-synuclein. Plasmin is a serine protease with a role in various physiological processes, including tissue and synaptic remodeling, inflammation regulation, and modulation of neurotrophic factors. It has also been shown that plasmin is able to cleave extracellular alpha-synuclein in neuronal cell cultures. The plasminogen activator inhibitor-1 (PAI-1) and the tissue plasminogen activator (tPA) regulate the synthesis and activity of plasmin in the brain. We measured the serum levels of tPA and PAI-1 in 30 DLB, 10 PD, and 12 MSA patients and compared them to 10 adults (controls). tPA and PAI-1 serum protein concentrations were quantified by ELISA and compared across the groups. The findings demonstrated that PAI-1 serum levels were increased in DLB (p &lt; 0.05), PD (p &lt; 0.01), and MSA (p &lt; 0.001) patients as compared to controls. In addition, MSA patients had higher PAI-1 serum levels (p &lt; 0.01) as compared to DLB patients, showing the highest PAI-1 levels among all groups. No differences in tPA serum levels were found among groups. Our findings suggest an involvement of plasmin system in these synucleinopathies although there are some limitations due to the heterogeneity of our cohort of participants. Thus, these data must be seen as preliminary observations and further studies in larger and more homogenous cohorts are needed before drawing definitive conclusions.

Název v anglickém jazyce

Dementia with Lewy Bodies (DLB), Parkinson's Disease (PD), and Multiple System Atrophy (MSA) Are Synucleopathies Characterized by Increased Serum Levels of Plasminogen Activator Inhibitor-1 (PAI-1)

Popis výsledku anglicky

Dementia with Lewy bodies (DLB), Parkinson&apos;s disease (PD), and multiple system atrophy (MSA) are neurodegenerative disorders characterized by abnormal accumulation of alpha-synuclein. Plasmin is a serine protease with a role in various physiological processes, including tissue and synaptic remodeling, inflammation regulation, and modulation of neurotrophic factors. It has also been shown that plasmin is able to cleave extracellular alpha-synuclein in neuronal cell cultures. The plasminogen activator inhibitor-1 (PAI-1) and the tissue plasminogen activator (tPA) regulate the synthesis and activity of plasmin in the brain. We measured the serum levels of tPA and PAI-1 in 30 DLB, 10 PD, and 12 MSA patients and compared them to 10 adults (controls). tPA and PAI-1 serum protein concentrations were quantified by ELISA and compared across the groups. The findings demonstrated that PAI-1 serum levels were increased in DLB (p &lt; 0.05), PD (p &lt; 0.01), and MSA (p &lt; 0.001) patients as compared to controls. In addition, MSA patients had higher PAI-1 serum levels (p &lt; 0.01) as compared to DLB patients, showing the highest PAI-1 levels among all groups. No differences in tPA serum levels were found among groups. Our findings suggest an involvement of plasmin system in these synucleinopathies although there are some limitations due to the heterogeneity of our cohort of participants. Thus, these data must be seen as preliminary observations and further studies in larger and more homogenous cohorts are needed before drawing definitive conclusions.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/LX22NPO5107" target="_blank" >LX22NPO5107: Národní ústav pro neurologický výzkum</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ACS OMEGA

ISSN

2470-1343

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

23

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

24194-24199

Kód UT WoS článku

001503723600001

EID výsledku v databázi Scopus

—